申请人:Dainippon Pharmaceutical Co., Ltd.
公开号:US03948928A1
公开(公告)日:1976-04-06
3-Substituted-1,2-benzisoxazole derivative of the following formula: ##SPC1## Wherein R.sub.1 is hydrogen, hydroxy, nitro, alkyl, alkoxy, halogen or amino; R.sub.2 is hydroxyamino, amino, hydrazino, mono- or di- alkyl substituted amino, aralkylamino, acyloxyamino, morpholino, piperazine which is unsubstituted or substituted with alkyl, aralkyl or aryl at 4 position, or pyrrolidino, or R.sub.2 may combine with imino group and form together with the adjacent carbon atom a heterocyclic ring such as imidazoline or tetrahydropyrimidine; and n is an integer of 0 to 3, and its pharmaceutically acceptable acid addition salt, and preparation thereof. The present compounds show valuable pharmacological properties, such as anti-reserpine activity, central nervous depressing activity, anti-hypertensive activity and l-dopa potentiating activity.
以下是上述化学式的中文翻译:3-取代-1,2-苯并异噁唑衍生物的化学式如下:其中R.sub.1为氢、羟基、硝基、烷基、烷氧基、卤素或氨基;R.sub.2为羟胺基、氨基、叠氮基、单取代或双取代的烷基氨基、芳基烷基氨基、酰氧氨基、吗啉基、哌嗪基(在4位未取代或取代为烷基、芳基或芳基烷基),或吡咯啉基,或R.sub.2可能与亚胺基结合,并与相邻的碳原子形成杂环环,如咪唑啉或四氢嘧啶;n为0至3的整数,以及其药学上可接受的酸盐和制备方法。这些化合物具有有价值的药理特性,如抗利血平活性、中枢神经抑制活性、抗高血压活性和L-多巴增强活性。